The safety of etanercept for the treatment of plaque psoriasis

References

• AbelLCasanovaJLGenetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritanceAm J Hum Genet200067274710882573
   PubMedGoogle Scholar
• AdamsAEZwickerJCurielCAggressive cutaneous T-cell lymphomas after TNFalpha blockadeJ Am Acad Dermatol200451660215389210
   PubMed Web of Science ®Google Scholar
• ArendSMBreedveldFCvan DisselJTTNF-alpha blockade and tuberculosis: better look before you leapNeth J Med2003611111912852719
   PubMed Web of Science ®Google Scholar
• ArnottCHScottKAMooreRJTumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathwayOncogene20022147283812101411
   PubMed Web of Science ®Google Scholar
• ArunkumarPCrookTBallardJDisseminated histoplasmosis presenting as pancytopenia in a methotrexate-treated patientAm J Hematol20047786715307113
   PubMedGoogle Scholar
• BaecklundEAsklingJRosenquistRRheumatoid arthritis and malignant lymphomasCurr Opin Rheumatol2004162546115103253
   PubMed Web of Science ®Google Scholar
• BaecklundEEkbomASparenPDisease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ199831718019665898
   PubMed Web of Science ®Google Scholar
• BaecklundEIliadouAAsklingJAssociation of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis Rheum20065469270116508929
   PubMed Web of Science ®Google Scholar
• BaecklundESundstromCEkbomALymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphomaArthritis Rheum20034815435012794821
   PubMed Web of Science ®Google Scholar
• BaghaiMOsmonDRWolkDMFatal sepsis in a patient with rheumatoid arthritis treated with etanerceptMayo Clin Proc200176653611393506
   PubMed Web of Science ®Google Scholar
• BalkwillFRNaylorMSMalikSTumour necrosis factor as an anticancer gentEur J Cancer19902664142144756
   PubMedGoogle Scholar
• Baran-MarszakFLaguillierCYoulyouzIEffect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virusCytokine2006333374516713282
   PubMedGoogle Scholar
• BaumelouEGuiguetMMaryJYEpidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic AnemiaBlood199381147188453094
   PubMedGoogle Scholar
• BellesiMLogulloFDi BellaPCNS demyelination during anti-tumor necrosis factor alpha therapyJ Neurol2006253668916311894
   PubMed Web of Science ®Google Scholar
• BerryCLModification of the host response in experimental histoplasmosisJ Pathol196997653645354043
   PubMedGoogle Scholar
• BibboCGoldbergJWInfectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapyFoot Ankle Int200425331515134615
   PubMed Web of Science ®Google Scholar
• BleuminkGSTer BorgEJRamselaarCGEtanercept-induced subacute cutaneous lupus erythematosusRheumatology (Oxford)20014013171911709621
   PubMed Web of Science ®Google Scholar
• BothaTRyffelBReactivation of latent tuberculosis infection in TNF-deficient miceJ Immunol200317131101812960337
   PubMed Web of Science ®Google Scholar
• BozkurtBTorre-AmioneGWarrenMSResults of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failureCirculation20011031044711222463
   PubMed Web of Science ®Google Scholar
• BrownSLGreeneMHGershonSKTumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug AdministrationArthritis Rheum2002463151812483718
   PubMed Web of Science ®Google Scholar
• CairnsAPDuncanMKHinderAENew onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritisAnn Rheum Dis2002611031212379532
   PubMed Web of Science ®Google Scholar
• CalabreseLHZeinNVassilopoulosDSafety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infectionAnn Rheum Dis200463Suppl 2ii182415479865
   PubMedGoogle Scholar
• CanoMVHajjehRAThe epidemiology of histoplasmosis: a reviewSemin Respir Infect2001161091811521243
   PubMedGoogle Scholar
• CarlsonERothfieldNEtanercept-induced lupus-like syndrome in a patient with rheumatoid arthritisArthritis Rheum20034811656 author reply 116612687569
   PubMed Web of Science ®Google Scholar
• CasanovaJLAbelLGenetic dissection of immunity to mycobacteria: the human modelAnnu Rev Immunol20022058162011861613
   PubMed Web of Science ®Google Scholar
• CatrinaAITrollmoCAf KlintEEvidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended reportArthritis Rheum200552617215641091
   PubMed Web of Science ®Google Scholar
• [CDC] Centers for Disease Control and PreventionTuberculosis associated with blocking agents against tumor necrosis factor-alpha— California, 2002–2003MMWR Morb Mortal Wkly Rep200453683615295313
   PubMedGoogle Scholar
• ChangETSmedbyKEHjalgrimHMedication use and risk of non-Hodgkin’s lymphomaAm J Epidemiol20051629657416192343
   PubMed Web of Science ®Google Scholar
• ChoyEHPanayiGSCytokine pathways and joint inflammation in rheumatoid arthritisN Engl J Med20013449071611259725
   PubMed Web of Science ®Google Scholar
• CisternasMGutierrezMJacobelliSSuccessful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et alArthritis Rheum20024631078 author reply 3108–912428265
   PubMed Web of Science ®Google Scholar
• CreaseyAAReynoldsMTLairdWCures and partial regression of murine and human tumors by recombinant human tumor necrosis factorCancer Res1986465687903756916
   PubMed Web of Science ®Google Scholar
• CushJJSafety of new biologic therapies in rheumatoid arthritisBulletin on the Rheumatic Diseases2004a217
   Google Scholar
• CushJJSafety overview of new disease-modifying antirheumatic drugsRheum Dis Clin North Am2004b3023755, v15172038
   PubMed Web of Science ®Google Scholar
• CushJJUnusual toxicities with TNF inhibition: heart failure and drug-induced lupusClin Exp Rheumatol2004c22S141715552528
   PubMedGoogle Scholar
• DaherSFonsecaFRibeiroOGTumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortionEur J Obstet Gynecol Reprod Biol19998377910221614
   PubMed Web of Science ®Google Scholar
• DebandtMSibiliaJLe LoetXSystemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national surveyArthritis Res Ther20057R5455115899041
   PubMedGoogle Scholar
• De FranchisRHadengueALauGEASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version)J Hepatol200339Suppl 1S32514708673
   PubMed Web of Science ®Google Scholar
• DebandtMVittecoqODescampsVAnti-TNF-alpha-induced systemic lupus syndromeClin Rheumatol200322566112605321
   PubMed Web of Science ®Google Scholar
• DembicZLoetscherHGublerUTwo human TNF receptors have similar extracellular, but distinct intracellular, domain sequencesCytokine1990223171966549
   PubMedGoogle Scholar
• DinarelloCAAnti-cytokine therapeutics and infectionsVaccine200321Suppl 2S243412763679
   PubMedGoogle Scholar
• DinarelloCADifferences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairmentJ Rheumatol Suppl20057440715742464
   PubMedGoogle Scholar
• DoranMFCrowsonCSPondGRFrequency of infection in patients with rheumatoid arthritis compared with controls: a population-based studyArthritis Rheum2002a4622879312355475
   PubMed Web of Science ®Google Scholar
• DoranMFCrowsonCSPondGRPredictors of infection in rheumatoid arthritisArthritis Rheum2002b46229430012355476
   PubMed Web of Science ®Google Scholar
• DyeCScheeleSDolinPConsensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring ProjectJAMA19992826778610517722
   PubMed Web of Science ®Google Scholar
• EbersGCSadovnickADThe geographic distribution of multiple sclerosis: a reviewNeuroepidemiology199312158327018
   PubMedGoogle Scholar
• EdwardsKRMowadCMTylerWBWorsening injection site reactions with continued use of etanerceptJ Drugs Dermatol20032184712852371
   PubMedGoogle Scholar
• EhlersSTumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?Clin Infect Dis200541Suppl 3S19920315983900
   PubMed Web of Science ®Google Scholar
• EhlersSHolscherCScheuSThe lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenesJ Immunol200317052101812734369
   PubMedGoogle Scholar
• EkstromKHjalgrimHBrandtLRisk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relativesArthritis Rheum2003489637012687538
   PubMed Web of Science ®Google Scholar
• ElahiMMMatataBMGenetic diversity of tumour necrosis factor: implications on cardiovascular complications of polymorphisms at position -308 in the promoter regionThe Cardiology2005117988
   Google Scholar
• ElkayamOCaspiDReitblattTThe effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitisSemin Arthritis Rheum200433283814978666
   PubMed Web of Science ®Google Scholar
• [FDA] Food and Drug Administration Briefing DocumentUpdate on the TNF-blocking agents [online]2003 Acessed on 22 October 2006. URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF. Briefing.pdf
   Google Scholar
• FilellaXBladeJGuillermoALCytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myelomaCancer Detect Prev1996205268907203
   PubMedGoogle Scholar
• FisherCJJrAgostiJMOpalSMTreatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study GroupN Engl J Med199633416977028637514
   PubMed Web of Science ®Google Scholar
• FleischmannRYocumDDoes safety make a difference in selecting the right TNF antagonist?Arthritis Res Ther20046Suppl 2S121815228616
   PubMed Web of Science ®Google Scholar
• FominICaspiDLevyVVaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockersAnn Rheum Dis200665191416014674
   PubMed Web of Science ®Google Scholar
• FreedmanMHCohenAGrunbergerTCentral role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemiaBr J Haematol1992804081311195
   PubMed Web of Science ®Google Scholar
• GalariaNAWerthVPSchumacherHRLeukocytoclastic vasculitis due to etanerceptJ Rheumatol2000272041410955351
   PubMed Web of Science ®Google Scholar
• GardamMAKeystoneECMenziesRAnti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementLancet Infect Dis200331485512614731
   PubMed Web of Science ®Google Scholar
• GarrisonLMcDonnellNDEtanercept: therapeutic use in patients with rheumatoid arthritisAnn Rheum Dis199958Suppl 1I65910577976
   PubMed Web of Science ®Google Scholar
• GelfandJMBerlinJvan VoorheesALymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United KingdomArch Dermatol20031391425914623702
   PubMed Web of Science ®Google Scholar
• GelfamdJMShinDBNeimannALThe risk of lymphoma in patients with psoriasisJ Invest Dermatol2006
   Google Scholar
• GottliebGSLesserCFHolmesKKDisseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonistsClin Infect Dis2003378384012955647
   PubMed Web of Science ®Google Scholar
• GrussHJDowerSKThe TNF ligand superfamily and its relevance for human diseasesCytokines Mol Ther19951751059384666
   PubMedGoogle Scholar
• HamonMBierneHCossartPListeria monocytogenes: a multifaceted modelNat Rev Microbiol200644233416710323
   PubMed Web of Science ®Google Scholar
• HAMOSHMDigestion in the newbornClin Perinatol1996231912098780901
   PubMed Web of Science ®Google Scholar
• HanSZhangXMarinovaEBlockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 responseArthritis Rheum2005523202916200624
   PubMedGoogle Scholar
• Hannuksela-SvahnAPukkalaELaaraEPsoriasis, its treatment, and cancer in a cohort of Finnish patientsJ Invest Dermatol20001145879010692122
   PubMed Web of Science ®Google Scholar
• HaraouiBKeystoneEMusculoskeletal manifestations and autoimmune diseases related to new biologic agentsCurr Opin Rheumatol2006189610016344625
   PubMed Web of Science ®Google Scholar
• HavellEAEvidence that tumor necrosis factor has an important role in antibacterial resistanceJ Immunol1989143289492509559
   PubMed Web of Science ®Google Scholar
• HellmichBLamprechtPGrossWLAdvances in the therapy of Wegener’s granulomatosisCurr Opin Rheumatol200618253216344616
   PubMed Web of Science ®Google Scholar
• HendersonTRHamoshMArmandMGastric proteolysis in preterm infants fed mother’s milk or formulaAdv Exp Med Biol2001501403811787709
   PubMedGoogle Scholar
• HerbeinGO’BrienWATumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesisProc Soc Exp Biol Med20002232415710719836
   PubMed Web of Science ®Google Scholar
• HermosoMAMatsuguchiTSmoakKGlucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expressionMol Cell Biol20042447435615143169
   PubMed Web of Science ®Google Scholar
• HPB CanadaDear Healthcare Professional Letter (2006 Jan 18) [online]2006 Accessed on 15 December 2006. URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/2006/anti-tnf_therapy_pc-cp_e.html
   Google Scholar
• ImanishiJExpression of cytokines in bacterial and viral infections and their biochemical aspectsJ Biochem (Tokyo)20001275253010739941
   PubMedGoogle Scholar
• ImperatoAKSmilesSAbramsonSBLong-term risks associated with biologic response modifiers used in rheumatic diseasesCurr Opin Rheumatol20041619920515103245
   PubMed Web of Science ®Google Scholar
• IoannidisJPMulrowCDGoodmanSNAdverse events: the more you search, the more you findAnn Intern Med200614429830016490917
   PubMedGoogle Scholar
• JarvisBFauldsDEtanercept: a review of its use in rheumatoid arthritisDrugs1999579456610400407
   PubMed Web of Science ®Google Scholar
• JasmerRMNahidPHopewellPCClinical practice. Latent tuberculosis infectionN Engl J Med20023471860612466511
   PubMed Web of Science ®Google Scholar
• JonsdottirTForslidJvan VollenhovenATreatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodiesAnn Rheum Dis2004631075815066863
   PubMed Web of Science ®Google Scholar
• KanalySTNashleanasMHondowiczBTNF receptor p55 is required for elimination of inflammatory cells following control of intracellular pathogensJ Immunol19991633883910490988
   PubMed Web of Science ®Google Scholar
• KapetanovicMCSaxneTSjoholmAInfluence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritisRheumatology (Oxford)2006451061116287919
   PubMed Web of Science ®Google Scholar
• KatoIKoenigKLBaptisteMSHistory of antibiotic use and risk of non-Hodgkin’s lymphoma (NHL)Int J Cancer20031079910512925963
   PubMedGoogle Scholar
• KavanaughATutuncuZCatalan-SanchezTUpdate on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritisCurr Opin Rheumatol2006183475316763453
   PubMed Web of Science ®Google Scholar
• KeaneJTumor necrosis factor blockers and reactivation of latent tuberculosisClin Infect Dis200439300215306994
   PubMed Web of Science ®Google Scholar
• KeaneJTNF-blocking agents and tuberculosis: new drugs illuminate an old topicRheumatology (Oxford)2005447142015741198
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345109810411596589
   PubMed Web of Science ®Google Scholar
• KeystoneECSafety issues related to emerging therapies for rheumatoid arthritisClin Exp Rheumatol200422S1485015552529
   PubMedGoogle Scholar
• KeystoneECSafety of biologic therapies—an updateJ Rheumatol Suppl20057481215742458
   PubMedGoogle Scholar
• KeystoneECDinarelloCCMechanism of action of tumor necrosis factor antagonistsJ Rheumatol Suppl2005741215742456
   PubMedGoogle Scholar
• KhanGEpstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin’s lymphoma?Exp Hematol20063439940616569586
   PubMed Web of Science ®Google Scholar
• KhannaDMcMahonMFurstDESafety of tumour necrosis factor-alpha antagonistsDrug Saf2004273072415061685
   PubMed Web of Science ®Google Scholar
• KhannaMShirodkarMAGottliebABEtanercept therapy in patients with autoimmunity and hepatitis CJ Dermatolog Treat2003142293214660270
   PubMedGoogle Scholar
• KollerHKieseierBCJanderSChronic inflammatory demyelinating polyneuropathyN Engl J Med2005a35213435615800230
   PubMed Web of Science ®Google Scholar
• KollerHSchroeterMKieseierBCChronic inflammatory demyelinating polyneuropathy—update on pathogenesis, diagnostic criteria and therapyCurr Opin Neurol2005b18273815891411
   PubMed Web of Science ®Google Scholar
• Korth-BradleyJMRubinASHannaRKThe pharmacokinetics of etanercept in healthy volunteersAnn Pharmacother200034161410676822
   PubMed Web of Science ®Google Scholar
• KrishnanEFriesJFMeasuring effectiveness of drugs in observational databanks: promises and perilsArthritis Res Ther2004641415059263
   PubMed Web of Science ®Google Scholar
• KwonHJCoteTRCuffeMSCase reports of heart failure after therapy with a tumor necrosis factor antagonistAnn Intern Med20031388071112755552
   PubMed Web of Science ®Google Scholar
• La MontagnaGValentiniGListeria monocytogenes meningitis in a patient receiving etanercept for Still’s diseaseClin Exp Rheumatol20052312115789900
   PubMedGoogle Scholar
• LebwohlMNew developments in the treatment of psoriasisArch Dermatol2002138686812020234
   PubMed Web of Science ®Google Scholar
• LeeJHSlifmanNRGershonSKLife-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanerceptArthritis Rheum20024625657012384912
   PubMed Web of Science ®Google Scholar
• LemenseG PSahnSAOpportunistic infection during treatment with low dose methotrexateAm J Respir Crit Care Med1994150258608025760
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept as monotherapy in patients with psoriasisN Engl J Med200334920142214627786
   PubMed Web of Science ®Google Scholar
• LiebowitzDEpstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patientsN Engl J Med19983381413219580648
   PubMed Web of Science ®Google Scholar
• ListingJStrangfeldAKarySInfections in patients with rheumatoid arthritis treated with biologic agentsArthritis Rheum20055234031216255017
   PubMed Web of Science ®Google Scholar
• Liz-GranaMGomez-Reino CarnotaJJTumour necrosis factor. genetics, cell action mechanism and involvement in inflammationAlergol Immunol Clin2001161409
   Google Scholar
• [LMS-UBC] The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupTNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeurology1999534576510449104
   PubMedGoogle Scholar
• LokASMcMahonBJChronic hepatitis B: update of recommendationsHepatology2004398576114999707
   PubMed Web of Science ®Google Scholar
• LuheshiGNStefferlATurnbullAVFebrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-alpha in the ratAm J Physiol1997272R86289087648
   PubMedGoogle Scholar
• MagnanoMDRobinsonWHGenoveseMCDemyelination and inhibition of tumor necrosis factor (TNF)Clin Exp Rheumatol200422S1344015552527
   PubMed Web of Science ®Google Scholar
• MalikSTNaylorMSEastNCells secreting tumour necrosis factor show enhanced metastasis in nude miceEur J Cancer199026103142148875
   PubMed Web of Science ®Google Scholar
• MannDLMcMurrayJJPackerMTargeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)Circulation2004109159460215023878
   PubMed Web of Science ®Google Scholar
• MarinoMWDunnAGrailDCharacterization of tumor necrosis factor-deficient miceProc Natl Acad Sci U S A199794809389223320
   PubMed Web of Science ®Google Scholar
• MarshallRWMarshallVJHullRDisease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse eventRheumatology (Oxford)2006453623 author reply 363–416332952
   PubMedGoogle Scholar
• MeasePJGoffeBSMetzJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet20003563859010972371
   PubMed Web of Science ®Google Scholar
• MeyerRMAmbinderRFStroobantsSHodgkin’s lymphoma: evolving concepts with implications for practiceHematology (Am Soc Hematol Educ Program)200418420215561683
   PubMedGoogle Scholar
• MichelMDuvouxCHezodeCFulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s diseaseJ Rheumatol2003301624512858469
   PubMed Web of Science ®Google Scholar
• MidgardRGronningMRiiseTMultiple sclerosis and chronic inflammatory diseases. A case-control studyActa Neurol Scand19969332288800342
   PubMedGoogle Scholar
• MiseryLPerrotJLGentil-PerretADermatological complications of etanercept therapy for rheumatoid arthritisBr J Dermatol2002146334511903255
   PubMed Web of Science ®Google Scholar
• MitsosLMCardonLRRyanLSusceptibility to tuberculosis: a locus on mouse chromosome 19 (Trl-4) regulates Mycobacterium tuberculosis replication in the lungsProc Natl Acad Sci U S A200310066101512740444
   PubMedGoogle Scholar
• MohanAKEdwardsETCoteTRDrug-induced systemic lupus erythematosus and TNF-alpha blockersLancet200236064612241965
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRDemyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritidesArthritis Rheum2001442862911762947
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRLeukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agentsJ Rheumatol2004311955815468359
   PubMed Web of Science ®Google Scholar
• MohlerKMTorranceDSSmithCASoluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonistsJ Immunol19931511548618393046
   PubMed Web of Science ®Google Scholar
• MooreRJOwensDMStampGMice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesisNat Med199958283110395330
   PubMed Web of Science ®Google Scholar
• MooreTALauHYCogenALAnti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injuryShock2003203091514501943
   PubMedGoogle Scholar
• MooreTALauHYCogenALDefective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alphaClin Infect Dis200541Suppl 3S2131715983903
   PubMedGoogle Scholar
• MukhtyarCLuqmaniRCurrent state of tumour necrosis factor {alpha} blockade in Wegener’s granulomatosisAnn Rheum Dis200564Suppl 4iv31616239383
   PubMedGoogle Scholar
• MulrowCLanghornePGrimshawJIntegrating heterogeneous pieces of evidence in systematic reviewsAnn Intern Med1997127989959412305
   PubMed Web of Science ®Google Scholar
• MurakamiTOkamuraCMatsuzakiSPrediction of pregnancy in infertile women with endometriosisGynecol Obstet Invest200253Suppl 1263211834865
   PubMedGoogle Scholar
• NadarajahKPritchardCListeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritisJ Clin Rheumatol200511120216357718
   PubMedGoogle Scholar
• NeteaMGRadstakeTJoostenLASalmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expressionArthritis Rheum2003481853712847679
   PubMedGoogle Scholar
• O’BrienDPBrilesDESzalaiAJTumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infectionsInfect Immun1999675956019916064
   PubMed Web of Science ®Google Scholar
• ObayashiHHasegawaGFukuiMTumor necrosis factor microsatellite polymorphism influences the development of insulin dependency in adult-onset diabetes patients with the DRB1*1502-DQB1*0601 allele and anti-glutamic acid decarboxylase antibodiesJ Clin Endocrinol Metab20008533485110999832
   PubMedGoogle Scholar
• OldLJTumor necrosis factor (TNF)Science198523063022413547
   PubMed Web of Science ®Google Scholar
• OllerosMLGulerRVesinDContribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infectionsAm J Pathol200516611092015793291
   PubMedGoogle Scholar
• OstensenMEigenmannGOEtanercept in breast milkJ Rheumatol20043110171815124283
   PubMed Web of Science ®Google Scholar
• OstuniPBotsiosCPunziLHepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexateAnn Rheum Dis200362686712810441
   PubMed Web of Science ®Google Scholar
• PaglianoPAttanasioVFuscoUDoes etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?Ann Rheum Dis200463462315020347
   PubMed Web of Science ®Google Scholar
• PalladinoMAJrPattonJSFigariISPossible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alphaCiba Found Symp198713121383330012
   PubMedGoogle Scholar
• PalladinoMAJrSrivastavaPKOettgenHFExpression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomasCancer Res198747507493497717
   PubMedGoogle Scholar
• PappKAEtanercept in psoriasisExpert Opin Pharmacother2004521394615461549
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMA global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol200515213041215948997
   PubMed Web of Science ®Google Scholar
• PetersonJRHsuFCSimkinPAEffect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infectionAnn Rheum Dis20036210788214583571
   PubMed Web of Science ®Google Scholar
• PfefferKBiological functions of tumor necrosis factor cytokines and their receptorsCytokine Growth Factor Rev2003141859112787558
   PubMed Web of Science ®Google Scholar
• PoppemaSImmunobiology and pathophysiology of hodgkin lymphomasHematology (Am Soc Hematol Educ Program)2005231816304386
   PubMedGoogle Scholar
• RachapalliSO’DauntSSeptic arthritis due to Listeria monocytogenes in a patient receiving etanerceptArthritis Rheum20055298715751076
   PubMedGoogle Scholar
• RajakulendranSDeightonCDelayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanerceptRheumatology (Oxford)2004431588915564639
   PubMed Web of Science ®Google Scholar
• RasmussenSKUrhammerSAJensenJNThe −238 and −308 G→A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish CaucasiansJ Clin Endocrinol Metab2000851731410770222
   PubMedGoogle Scholar
• RenardNRibeiroPWarzochaKModulation of costimulatory molecules on follicular lymphoma cells by TNF and CD40Leuk Lymphoma1999333314110221513
   PubMed Web of Science ®Google Scholar
• RickinsonABKieffEKnipeDMHowleyPMEpstein-Barr virusVirology1996PhiladelphiaLippincott-Raven
   Google Scholar
• RijneveldAWFlorquinSHartungTAnti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumoniaJ Infect Dis2003188282512854084
   PubMedGoogle Scholar
• RoachDRBeanAGDemangelCTNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infectionJ Immunol20021684620711971010
   PubMed Web of Science ®Google Scholar
• RotheJLesslauerWLotscherHMice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesNature19933647988028395024
   PubMed Web of Science ®Google Scholar
• RoyVHammerschmidtDEDisseminated histoplasmosis following prolonged low-dose methotrexate therapyAm J Hematol200063596010602172
   PubMedGoogle Scholar
• SadovnickADArmstrongHRiceGPA population-based study of multiple sclerosis in twins: updateAnn Neurol19933328158498811
   PubMed Web of Science ®Google Scholar
• SaundersBMTranSRuulsSTransmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infectionJ Immunol20051744852915814712
   PubMed Web of Science ®Google Scholar
• SchettGHerakPGraningerWListeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literatureJ Clin Microbiol20054325374115872306
   PubMed Web of Science ®Google Scholar
• SchiemannUKellnerHGastrointestinal side effects in the therapy of rheumatologic diseasesZ Gastroenterol2002409374312436372
   PubMedGoogle Scholar
• SchlaakJFTullyGLohrHFHBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokinesClin Exp Immunol19991155081410193426
   PubMed Web of Science ®Google Scholar
• SfikakisPPIliopoulosAElezoglouAPsoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reactionArthritis Rheum20055225131816052599
   PubMed Web of Science ®Google Scholar
• ShakoorNMichalskaMHarrisCADrug-induced systemic lupus erythematosus associated with etanercept therapyLancet20023595798011867114
   PubMed Web of Science ®Google Scholar
• ShepherdGMHypersensitivity reactions to drugs: evaluation and managementMt Sinai J Med2003701132512634903
   PubMed Web of Science ®Google Scholar
• SkyttaEPohjankoskiHSavolainenAEtanercept and urticaria in patients with juvenile idiopathic arthritisClin Exp Rheumatol200018533410949736
   PubMed Web of Science ®Google Scholar
• SlifmanNRGershonSKLeeJHListeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agentsArthritis Rheum2003483192412571839
   PubMed Web of Science ®Google Scholar
• SmedbyKEHjalgrimHAsklingJAutoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtypeJ Natl Cancer Inst200698516016391371
   PubMed Web of Science ®Google Scholar
• SmithJGMageeDMWilliamsDMTumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatumJ Infect Dis19901621349532230264
   PubMedGoogle Scholar
• SmithKJSkeltonHGRapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapyJ Am Acad Dermatol200145953611712048
   PubMed Web of Science ®Google Scholar
• SokkaTRheumatoid arthritis databasesRheum Dis Clin North Am20043076981vi15488692
   PubMed Web of Science ®Google Scholar
• SpahnTWEugsterHPFontanaARole of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathwayInfect Immun20057370778816239501
   PubMed Web of Science ®Google Scholar
• StefferlAHopkinsSJRothwellNJThe role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the ratBr J Pharmacol19961181919248864524
   PubMedGoogle Scholar
• StengerSImmunological control of tuberculosis: role of tumour necrosis factor and moreAnn Rheum Dis200564Suppl 4iv24816239381
   PubMedGoogle Scholar
• StoneJHHolbrookJTMarriottMASolid malignancies among patients in the Wegener’s Granulomatosis Etanercept TrialArthritis Rheum20065416081816646004
   PubMed Web of Science ®Google Scholar
• SukalSANadimintiLGransteinRDEtanercept and demyelinating disease in a patient with psoriasisJ Am Acad Dermatol200654160416384777
   PubMed Web of Science ®Google Scholar
• TakashimaKTatedaKMatsumotoTRole of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in miceInfect Immun199765257608975920
   PubMed Web of Science ®Google Scholar
• TartakovskyBBen-YairECytokines modulate preimplantation development and pregnancyDev Biol1991146345521864460
   PubMed Web of Science ®Google Scholar
• Torre-AmioneGVooletichMTFarmerJARole of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implicationsDrugs2000597455110804032
   PubMed Web of Science ®Google Scholar
• TorresDJanotLQuesniauxVFMembrane tumor necrosis factor confers partial protection to Listeria infectionAm J Pathol200516716778716314479
   PubMedGoogle Scholar
• TurnbullAVRivierCLRegulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of actionPhysiol Rev1999791719922367
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKEtanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialLancet2006367293516399150
   PubMed Web of Science ®Google Scholar
• Van OostenBWBarkhofFTruyenLIncreased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2Neurology199647153148960740
   PubMed Web of Science ®Google Scholar
• VoloshinDKLacomisDMcMahonDDisseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositisMuscle Nerve19951853157739641
   PubMedGoogle Scholar
• WallisRSBroderMWongJGranulomatous infections due to tumor necrosis factor blockade: correctionClin Infect Dis2004a391254515486857
   PubMed Web of Science ®Google Scholar
• WallisRSBroderMSWongJYGranulomatous infectious diseases associated with tumor necrosis factor antagonistsClin Infect Dis2004b381261515127338
   PubMed Web of Science ®Google Scholar
• WarzochaKBienvenuJCoiffierBMechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor systemEur Cytokine Netw1995683967578992
   PubMed Web of Science ®Google Scholar
• WarzochaKBienvenuJRibeiroPPlasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patientsBr J Cancer1998772357629649158
   PubMed Web of Science ®Google Scholar
• WarzochaKRibeiroPBienvenuJGenetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcomeBlood1998913574819572991
   PubMed Web of Science ®Google Scholar
• WarzochaKSallesGThe tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferationLeuk Lymphoma19982981929638978
   PubMed Web of Science ®Google Scholar
• WattsRAMusculoskeletal and systemic reactions to biological therapeutic agentsCurr Opin Rheumatol200012495210647954
   PubMed Web of Science ®Google Scholar
• WerthVPLevinsonAIEtanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistryArch Dermatol2001137953511453818
   PubMed Web of Science ®Google Scholar
• WeyandCMGoronzyJJKurtinPJLymphoma in rheumatoid arthritis: an immune system set up for failureArthritis Rheum200654685916508924
   PubMedGoogle Scholar
• [WGET] Wegener’s Granulomatosis Etanercept Trial Research GroupEtanercept plus standard therapy for Wegener’s granulomatosisN Engl J Med20053523516115673801
   PubMed Web of Science ®Google Scholar
• WiendlHHohlfeldRTherapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trialsBioDrugs20021618320012102646
   PubMed Web of Science ®Google Scholar
• WilliamsJDGriffithsCECytokine blocking agents in dermatologyClin Exp Dermatol2002275859012464154
   PubMed Web of Science ®Google Scholar
• WittyLASteinerFCurfmanMDisseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasisArch Dermatol19921289131739293
   PubMedGoogle Scholar
• WolfeFMichaudKHeart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapyAm J Med2004a1163051114984815
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKLymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patientsArthritis Rheum2004b5017405115188349
   PubMed Web of Science ®Google Scholar
• ZeinCOZeinNNAdvances in therapy for hepatitis C infectionMicrobes Infect2002412374612467765
   PubMed Web of Science ®Google Scholar
• ZeltserRValleLTanckCClinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion proteinArch Dermatol2001137893911453808
   PubMed Web of Science ®Google Scholar
• ZganiaczASantosuossoMWangJTNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infectionJ Clin Invest20041134011314755337
   PubMed Web of Science ®Google Scholar
• ZhouPMillerGSederRAFactors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gammaJ Immunol19981601359689570555
   PubMed Web of Science ®Google Scholar
• ZhouTMountzJDKimberlyRPImmunobiology of tumor necrosis factor receptor superfamilyImmunol Res2002263233612403370
   PubMedGoogle Scholar
• ZinmanBHanleyAJHarrisSBCirculating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitusJ Clin Endocrinol Metab199984278
   Google Scholar